FA
ABBV icon

Fagan Associates’s AbbVie ABBV Stock Holding History

Fagan Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-30,092
Closed -$1.88M – 96
2016
Q4 		$1.88M Buy
30,092
+422
+1% +$25.8K 1.09% 33
2016
Q3 		$1.87M Buy
29,670
+6,492
+28% +$420K 1.15% 31
2016
Q2 		$1.44M Buy
+23,178
New +$1.41M 0.92% 36

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Fagan Associates's ABBV Position: Q1 2017 in Review

Fagan Associates sold out of AbbVie (ABBV) in Q1 2017, closing a stake of 30,092 shares — an estimated $1.88M sold.

Fagan Associates first reported a position in ABBV in Q2 2016 and held it in 3 quarters. The position peaked at $1.88M in Q4 2016. 1,727 funds tracked by Wall St. Rank hold ABBV as of Q1 2017.

  • Fagan Associates reported no remaining AbbVie position as of Q1 2017 after selling out during the quarter.
  • Fagan Associates sold 30,092 AbbVie shares in Q1 2017, an estimated $1.88M.
  • Fagan Associates first reported a position in AbbVie in Q2 2016 and held it in 3 quarters.
  • Fagan Associates's AbbVie position peaked at $1.88M in Q4 2016.
  • 1,727 funds tracked by Wall St. Rank held AbbVie as of Q1 2017.

Based on Fagan Associates's 13F filing for Q1 2017, filed 9 May 2017.